Borsig Lubor, Wong Richard, Hynes Richard O, Varki Nissi M, Varki Ajit
Glycobiology Research and Training Center and the Cancer Center, Department of Medicine and Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093-0687, USA.
Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2193-8. doi: 10.1073/pnas.261704098.
P-selectin facilitates human carcinoma metastasis in immunodeficient mice by mediating early interactions of platelets with bloodborne tumor cells via their cell surface mucins, and this process can be blocked by heparin [Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M. & Varki, A. (2001) Proc. Natl. Acad. Sci. USA 98, 3352-3357]. Here we show similar findings with a murine adenocarcinoma in syngeneic immunocompetent mice but involving a different P-selectin ligand, possibly a sulfated glycolipid. Thus, metastatic spread can be facilitated by tumor cell selectin ligands other than mucins. Surprisingly, L-selectin expressed on endogenous leukocytes also facilitates metastasis in both the syngeneic and xenogeneic (T and B lymphocyte deficient) systems. PL-selectin double deficient mice show that the two selectins work synergistically. Although heparin can block both P- and L-selectin in vitro, the in vivo effect of a single heparin dose given before tumor cells seems to be completely accounted for by blockade of P-selectin function. Thus, L-selectin on neutrophils, monocytes, and/or NK cells has a role in facilitating metastasis, acting beyond the early time points wherein P-selectin mediates interactions of platelet with tumor cells.
P-选择素通过介导血小板与血行转移肿瘤细胞经由其细胞表面黏蛋白的早期相互作用,促进免疫缺陷小鼠体内的人类癌转移,且这一过程可被肝素阻断[博尔西格,L.,王,R.,费拉米斯科,J.,纳多,D. R.,瓦尔基,N. M. & 瓦尔基,A.(2001年)《美国国家科学院院刊》98,3352 - 3357]。在此我们在同基因免疫活性小鼠的鼠腺癌模型中展示了类似的发现,但涉及一种不同的P-选择素配体,可能是一种硫酸化糖脂。因此,除黏蛋白外,肿瘤细胞选择素配体也可促进转移扩散。令人惊讶的是,内源性白细胞上表达的L-选择素在同基因和异种(T和B淋巴细胞缺陷)系统中也促进转移。P-选择素和L-选择素双缺陷小鼠表明这两种选择素协同发挥作用。尽管肝素在体外可阻断P-选择素和L-选择素,但在肿瘤细胞接种前给予单次肝素剂量的体内效应似乎完全是由于P-选择素功能被阻断所致。因此,中性粒细胞、单核细胞和/或自然杀伤细胞上的L-选择素在促进转移中发挥作用,其作用时间点晚于P-选择素介导血小板与肿瘤细胞相互作用的早期时间点。